


For Patients with Metastatic Castrate Resistant Prostate Cancer

9984 Available Through the CTSU
 A Randomized Phase 2 Study of Cediranib in Combination with Olaparib versus Olaparib Alone in Men with Metastatic Castration Resistant Prostate Cancer

Patient Population - 84 Patients	Treatment Plan
<p>See Protocol Section 3 for Full Eligibility Details</p> <ul style="list-style-type: none"> Confirmed progressive, metastatic castration-resistant prostate adenocarcinoma <ul style="list-style-type: none"> Radiographic proof of metastasis Serum testosterone <50ng/dL Progression documented by rising PSA, new lesions on bone scan, or RECIST ≥2 prior lines therapy for mCRPC ≤2 prior <u>cytotoxic</u> chemotherapies for mCRPC Measurable disease by RECIST v1.1. Tumor lesion accessible for biopsy, cannot be used for RECIST response Agree to mandatory research tumor biopsies Controlled BP <140/90 mmHg; patients to monitor BP daily 	<p>See Protocol Section 5 for Full Treatment Details</p> <ul style="list-style-type: none"> Patients must continue or start LHRH or GnRH agonists 4 wks prior or have had orchiectomy Randomized 1:1 <ul style="list-style-type: none"> Group 1: Cediranib 30 mg PO qd + Olaparib 200 mg PO bid Group 2: Olaparib 200 mg PO bid Olaparib-only patients can cross over to the combination upon radiographic progression Treatment until disease progression or excessive toxicity Notes: <ul style="list-style-type: none"> Baseline and on-treatment biopsies One cycle = 28 days

Schema



Patient Enrollment

All Sites: Oncology Patient Enrollment Network (OPEN) <https://open.ctsu.org/open>

Protocol Information

CTSU Help Desk: 1-888-823-5923, CTSUcontract@westat.com, www.ctsu.org; NCT02893917

Please Enroll Your Eligible Patients!

Study Chair:

Joseph W. Kim, M.D.
Joseph.w.kim@yale.edu